bluebird bio, Inc. (NASDAQ:BLUE) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 54.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 748,299 shares of the biotechnology company’s stock after selling 899,247 shares during the quarter. Dimensional Fund Advisors LP owned about 0.68% of bluebird bio worth $736,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Allegheny Financial Group LTD acquired a new stake in bluebird bio in the second quarter worth about $25,000. Enterprise Bank & Trust Co bought a new stake in bluebird bio in the first quarter worth about $38,000. China Universal Asset Management Co. Ltd. raised its position in bluebird bio by 189.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 36,580 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 23,933 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in bluebird bio by 48.0% in the first quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 13,000 shares in the last quarter. Finally, Bayesian Capital Management LP bought a new stake in bluebird bio in the first quarter worth about $52,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Trading Up 2.3 %

NASDAQ:BLUE opened at $0.51 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.68 and a quick ratio of 0.57. bluebird bio, Inc. has a fifty-two week low of $0.45 and a fifty-two week high of $5.53. The stock’s 50-day moving average is $0.63 and its two-hundred day moving average is $0.90. The stock has a market cap of $55.32 million, a PE ratio of -0.68 and a beta of 0.75.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. bluebird bio had a negative net margin of 567.29% and a negative return on equity of 207.25%. The business had revenue of $18.57 million for the quarter. As a group, equities research analysts forecast that bluebird bio, Inc. will post -1.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BLUE has been the topic of several research reports. Barclays dropped their price target on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating on the stock in a research report on Thursday, August 15th. Bank of America dropped their price target on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. StockNews.com initiated coverage on shares of bluebird bio in a research report on Saturday, October 5th. They issued a “sell” rating on the stock. Robert W. Baird cut their price objective on bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, August 15th. Finally, Wells Fargo & Company cut their price objective on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Wednesday, September 25th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $4.63.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.